Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ScandiDos ABOSTO:SDOS -0.60%47 Return-on-Tangible-Asset is 1.28% as of Apr. 2026. GuruFocus rates OSTO:SDOS with a GF Score™ of 47/100 and a GF Value™ of kr1.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 856 Medical Devices & Instruments companies, ScandiDos AB ranks worse than 62.62% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ScandiDos AB's annualizedNet Income for the quarter that ended in Apr. 2026 was kr0.51 Mil. ScandiDos AB's average total tangible assets for the quarter that ended in Apr. 2026 was kr40.04 Mil. Therefore, ScandiDos AB's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2026 was 1.28%.
The historical rank and industry rank for ScandiDos AB's Return-on-Tangible-Asset or its related term are showing as below:
OSTO:SDOS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -48.16 Med: -26.12 Max: 0.62
Current: -7.96
During the past 13 years, ScandiDos AB's highest Return-on-Tangible-Asset was 0.62%. The lowest was -48.16%. And the median was -26.12%.
OSTO:SDOS's Return-on-Tangible-Asset is ranked worse than 62.62% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs OSTO:SDOS: -7.96
ScandiDos AB (OSTO:SDOS) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ScandiDos AB Return-on-Tangible-Asset Related Terms
ScandiDos AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SDOS vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, ScandiDos AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ScandiDos AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ScandiDos AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ScandiDos AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
What does a Return-on-Tangible-Asset of 1.28% mean?
ScandiDos AB (OSTO:SDOS) has a Return-on-Tangible-Asset of 1.28% as of Apr. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ScandiDos AB and its competitors. According to the industry distribution chart, ScandiDos AB ranks #536 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 62.6%.
Is ScandiDos AB's Return-on-Tangible-Asset too high?
ScandiDos AB's current Return-on-Tangible-Asset is 1.28%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. ScandiDos AB's value of 1.28% is 115.1% above this industry median. Based on the distribution chart, ScandiDos AB ranks #536 out of 856 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ScandiDos AB ranks #536 out of 856 companies for Return-on-Tangible-Asset. This places ScandiDos AB in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.60. ScandiDos AB's value of 1.28% is 115.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ScandiDos AB's current Return-on-Tangible-Asset of 1.28% is 115.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ScandiDos AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ScandiDos AB's current Return-on-Tangible-Asset is 1.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.14, compared to a current price of kr0.83 — trading 27.2% below its estimated fair value. The current Return-on-Tangible-Asset is 1.28% and 115.1% above the Medical Devices & Instruments industry median of 0.60. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current Return-on-Tangible-Asset is 1.28% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.83 is trading 27.2% below its estimated GF Value™ of kr1.14.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
Return-on-Tangible-Asset: 1.28%
GF Value™: kr1.14 vs. price of kr0.83 (27.2% below fair value)
Industry Position: 115.1% above the Medical Devices & Instruments median (#536 of 856)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for OSTO:SDOS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
